Tags for Structure. Probably Include a Heading Adagrasib (Krazati) Gains FDA Approval for NSCLC Targeting KRAS G12C
On December 15, 2022, the United States Food and Drug Administration granted approval to Adagrasib, marketed as Krazati, for the treatment of non‑small cell lung cancer. The drug is an oral anticancer agent that specifically inhibits the G12C mutant form of the KRAS GTPase, a driver of tumor growth in a subset of lung malignancies. Mirati Therapeutics, the biotechnology firm responsible for its development, designed Adagrasib to offer a targeted option for patients whose tumors harbor this particular genetic alteration.
The approval represents a step toward precision oncology, where therapy is matched to the molecular profile of the disease. By focusing on the KRAS G12C mutation, Adagrasib addresses a defined patient population that previously had limited treatment choices.
Clinicians can now prescribe the medication orally, which may improve convenience compared with intravenous regimens. Like all pharmaceuticals can cause side effects. The most frequently reported adverse reactions include diarrhea, nausea, fatigue, vomiting, musculoskeletal pain, hepatotoxicity, renal impairment, dyspnea, edema, decreased appetite, cough, pneumonia, dizziness, constipation, abdominal pain, QTc interval prolongation.
These reactions require vigilant monitoring and supportive care throughout therapy. Laboratory assessments performed during clinical studies revealed additional abnormalities that clinicians should watch for.
Observed changes included decreased lymphocytes, increased aspartate aminotransferase, decreased sodium, decreased hemoglobin, increased creatinine, decreased albumin, increased alanine aminotransferase, increased lipase, decreased platelets, decreased magnesium, and decreased potassium. Recognizing these shifts helps guide dose adjustments and interventions to mitigate potential toxicity. Beyond its current indication, the mechanism of Adagrasib suggests possible utility in other cancers driven by the KRAS G12C alteration.
Ongoing research and clinical trials are evaluating its activity in additional tumor types and exploring combination strategies with other anticancer agents. Such studies aim to define whether synergistic regimens can enhance efficacy while maintaining an acceptable safety profile. As the drug enters broader use, real‑world evidence will accumulate regarding its effectiveness and tolerability in everyday practice.
Data gathered from patients and healthcare providers will inform future labeling updates, dosing recommendations, and potential expanded indications. The medical community anticipates that continued investigation will clarify the full scope of Adagrasib’s benefit‑risk balance.
In summary, the December 2022 approval of Adagrasib marks a notable advancement in the treatment of non‑small cell lung cancer harboring the KRAS G12C mutation. It provides an oral, targeted therapeutic option, highlights the importance of biomarker‑driven therapy, and opens avenues for further study in NSCLC and other malignancies where the same genetic lesion plays a role.
